Response to MEK inhibition with trametinib and tyrosine kinase inhibition with imatinib in multifocal histiocytic sarcoma.

Response to MEK inhibition with trametinib and tyrosine kinase inhibition with imatinib in multifocal histiocytic sarcoma. Haematologica. 2017 Nov 02;: Authors: Voruz S, Cairoli A, Naveiras O, de Leval L, Missiaglia E, Homicsko K, Michielin O, Blum S PMID: 29097496 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/29097496?dopt=Abstract

Source: Haematologica - November 2, 2017 Category: Hematology Authors: Voruz S, Cairoli A, Naveiras O, de Leval L, Missiaglia E, Homicsko K, Michielin O, Blum S Tags: Haematologica Source Type: research

More News: Gleevec | Sarcomas